Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totaling 546 shares, a decrease of 88.1% from the April 30th total of 4,577 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.
Basilea Pharmaceutica Price Performance
OTCMKTS BPMUF opened at $65.10 on Friday. Basilea Pharmaceutica has a 12 month low of $57.70 and a 12 month high of $74.00. The stock’s fifty day moving average price is $69.05 and its 200-day moving average price is $67.51. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.11 and a quick ratio of 4.68.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- MarketBeat Week in Review – 05/25 – 05/29
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
